Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2712443 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL378111 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4712621 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4712172 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4712623 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL378632 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL11628436 | 0.98 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL20995129 | 0.98 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL24681635 | 0.82 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL14938190 | 0.82 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-7875643-B2 | (1S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-3-azabicyclo[3.1.0]hexane; or(1S,5R)-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; schizophrenia | GLAXO GROUP LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7803820-B2 | 3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7776904-B2 | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-06-17 | — | — | US | disclosed |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2009-01-29 | — | — | US | disclosed |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080167357-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| EP-1917242-A1 | AZABICYCLO [3.1.0]HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| EP-1917013-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007022935-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007022980-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, DRD2, HTR3C | SLC6A2 174/4885SLC6A4 334/4885SLC6A3 8/4885 |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | CHRNB3, DRD2, DRD3 | SLC6A2 1576/4885SLC6A4 1476/4885SLC6A3 76/4885 |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | SLC6A2 654/4885SLC6A4 660/4885SLC6A3 26/4885 |
| US-20080167357-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful as Modulators of Dopamine D3 Receptors | HTR5A, DRD3, HTR3C | SLC6A2 680/4885SLC6A4 334/4885SLC6A3 19/4885 |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | DRD3, HTR3C, HTR5A | SLC6A2 338/4885SLC6A4 194/4885SLC6A3 14/4885 |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | SLC6A2 654/4885SLC6A4 660/4885SLC6A3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.